Brain-Derived Neurotrophic Factor: A Novel Dynamically Regulated Therapeutic Modulator in Neurological Disorders

Sharma, Veerta; Singh, Thakur Gurjeet; Kaur, Amandeep; Mannan, Ashi; Dhiman, Sonia

doi:10.1007/s11064-022-03755-1

Cited by 32 publications

(13 citation statements)

References 209 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reduction in phosphorylated CREB protein leads to a decrease in BDNF expression and impaired axonal transport due to neuronal death or dysfunction results in reduced BDNF levels at the synapses. 28,29 The impaired downstream signaling pathways affects neuronal plasticity, synapse development, and cell survival, which could contribute to cognitive decline observed in AD patients. 12 In animal models, the correlation between central nervous system BDNF and cognitive performance was proved to be directly related.…”

Section: Discussionmentioning

confidence: 99%

Serum brain-derived neurotrophic factor levels as a predictor for Alzheimer disease progression

Tsai,

Lin,

Chen

et al. 2023

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Background: Brain-derived neurotrophic factor (BDNF) has been implicated in the pathophysiology of Alzheimer’s disease (AD), and decreased peripheral levels of this protein are associated with an increased risk of developing the disease. This study focuses on whether serum BDNF levels could be used as a predictor of AD progression. Methods: In this longitudinal observational study, we recruited cognition normal participants (N=98) and AD (N=442) from the Clinic at the Taipei Veterans General Hospital. We conducted a mini-mental status exam, a 12-item memory test, a categorical verbal fluency test, and a modified 15-item Boston naming test. A Serum BDNF level and Apolipoprotein E (APOE) allele status were measured. The AD patients were followed prospectively. Based on the difference of MMSE scores, these patients were divided into fast decliners (decline ≧ 3/year) and slow decliners (MMSE decline < 3/year). Logistic regression was conducted to examine the impact of serum BDNF levels and other factor on the likelihood of AD patients being slow decliners. Pearson’s correlation was used to estimate the relationship between serum BDNF levels and the score of neuropsychological tests. Results: In a logistic regression model containing serum BDNF levels, age, sex, APOE4 carrier status, education levels, and baseline MMSE score, higher serum BDNF levels were associated with a slower rate of cognitive decline in the AD group. Serum BDNF levels positively correlated with the results of multiple neuropsychological tests. Conclusion: BDNF is a protective factor against AD progression and likely plays a role in establishing a link between AD pathology and clinical manifestations.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum brain-derived neurotrophic factor levels as a predictor for Alzheimer disease progression

Tsai,

Lin,

Chen

et al. 2023

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

show abstract

“…The neuroprotective effects occurred via ObR receptor activation and involved activation of JAK-STAT, ERK, and growth factor receptor-bound protein 2 (GRB2) [ 124 ]. Leptin augments brain-derived neurotrophic factor (BDNF) following leptin receptor activation, with this factor being a key factor for survival of dopaminergic neurons, which is also diminished in PD [ 125 ]. As leptin and BDNF activate shared signaling pathways, such as PI3K and MAPK/ERK and some intermediary molecules, including SH2 and GRB2, leptin could induce positive feedback by increasing BDNF expression.…”

Section: Functionality Of Leptin and Its Involvement In Pathologymentioning

confidence: 99%

Recent Advances in the Knowledge of the Mechanisms of Leptin Physiology and Actions in Neurological and Metabolic Pathologies

Casado

Collado-Pérez

Frago

et al. 2023

IJMS

View full text Add to dashboard Cite

Excess body weight is frequently associated with low-grade inflammation. Evidence indicates a relationship between obesity and cancer, as well as with other diseases, such as diabetes and non-alcoholic fatty liver disease, in which inflammation and the actions of various adipokines play a role in the pathological mechanisms involved in these disorders. Leptin is mainly produced by adipose tissue in proportion to fat stores, but it is also synthesized in other organs, where leptin receptors are expressed. This hormone performs numerous actions in the brain, mainly related to the control of energy homeostasis. It is also involved in neurogenesis and neuroprotection, and central leptin resistance is related to some neurological disorders, e.g., Parkinson’s and Alzheimer’s diseases. In peripheral tissues, leptin is implicated in the regulation of metabolism, as well as of bone density and muscle mass. All these actions can be affected by changes in leptin levels and the mechanisms associated with resistance to this hormone. This review will present recent advances in the molecular mechanisms of leptin action and their underlying roles in pathological situations, which may be of interest for revealing new approaches for the treatment of diseases where the actions of this adipokine might be compromised.

show abstract

“…In this regard, brain-derived neurotrophic factor (BDNF) is the best-known and most abundant neurotrophin in the brain. As a consequence of addictive substance use, it leads to structural alterations in neural circuits, particularly in the brain areas associated with the reward circuitry in substance use disorder [ 11 , 19 ]. BDNF participates in several essential functions that are necessary to maintain the brain’s equilibrium state, including neuron survival, neurogenesis, neurotransmitter modulation, and, notably, synaptic adaptations and neuroplasticity changes [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Brain-derived neurotrophic factor serum levels as a candidate biomarker for withdrawal in crack heroin dependence

Charkhat Gorgich,

Rigi,

Fanaei

et al. 2024

Subst Abuse Treat Prev Policy

View full text Add to dashboard Cite

Background Crack heroin is a novel opiate derivative with highly addictive properties and unfamiliar health consequences. It causes a variety of brain dysfunctions that are mediated by neurochemical alterations and abnormal neuroplasticity. Brain-derived neurotrophic factor (BDNF) is a widely recognized biological marker implicated in the neuropathology of substance use during substance use disorder and withdrawal. Its involvement can significantly contribute to the severity of withdrawal symptoms. Hence, this study aimed to evaluate BDNF levels in crack heroin users before and after withdrawal. Methods In this cross-sectional study, 148 male participants were recruited and divided into two groups: persons with crack heroin use disorder (n = 74) and the controls (n = 74). The BDNF serum levels were measured in both crack heroin users and control groups upon hospitalization and again after twenty-one days of withdrawal using the enzyme-linked immunosorbent assay. Results The results demonstrated that BDNF levels in persons with crack heroin use disorder upon admission were significantly lower than the levels observed upon discharge and in the control group (p < 0.05). Additionally, a significant difference in BDNF levels was found between persons with crack heroin use disorder at admission and discharge (p = 0.038). Furthermore, BDNF levels showed an inverse correlation with the daily dose of substance use (r= -0.420, p = 0.03) and the duration of crack heroin use (r= -0.235, p = 0.001). Conclusions A progressive increment in BDNF levels during early detoxification is associated with the daily amount of substance use and the duration of substance use. Our findings suggest that changes in BDNF serum levels during crack heroin use disorder and withdrawal could serve as potential biomarkers for assessing the intensity of withdrawal symptoms and substance use-related behaviors.

show abstract

Brain-Derived Neurotrophic Factor: A Novel Dynamically Regulated Therapeutic Modulator in Neurological Disorders

Cited by 32 publications

References 209 publications

Serum brain-derived neurotrophic factor levels as a predictor for Alzheimer disease progression

Serum brain-derived neurotrophic factor levels as a predictor for Alzheimer disease progression

Recent Advances in the Knowledge of the Mechanisms of Leptin Physiology and Actions in Neurological and Metabolic Pathologies

Brain-derived neurotrophic factor serum levels as a candidate biomarker for withdrawal in crack heroin dependence

Contact Info

Product

Resources

About